Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if diagnosed early.
The MarketWatch News Department was not involved in the creation of this content. This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to ...
Humans and mice with a predisposition for ALS displayed altered sleep patterns before symptoms began, offering a potential novel diagnostic and treatment approach. The researchers started by ...
Palliative care physician, Dr. Mapa, and ALS researcher, Dr. Leitner, comment on the life and death for patients with ALS as well as future researchers.
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...
This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to accelerate the development of new ALS treatments ARLINGTON, Va., Dec. 4, 2025 ...
Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results